AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28395753 — intervention group
Group type: EXPERIMENTAL
Intervention: Selamectin/sarolaner spot-on formulation
Number of subjects: 30
Study 25792808 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-C1 treatment (daily intramuscular injections for 32 days)
Number of subjects: 47
Study 25792808 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-C1 treatment
Number of subjects: 47
Study 23327861 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 5 mg orally twice a day for 14 days
Number of subjects: 174
Study 23327861 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg orally once a day for 14 days
Number of subjects: 174
Study 21335259 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine dependence
Number of subjects: 1504
Study 21335259 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and contextual variables (e.g., ethnicity, gender, marital status, education, smoking in the workplace, number of smokers in the social network, number of supportive others)
Number of subjects: 1504
Study 21335259 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 1504
Study 19120329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 45
Study 19120329 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate 0.1%
Number of subjects: 45
Study 19120329 — intervention group
Group type: COMPARATOR
Intervention: Emollient
Number of subjects: 45
Study 17084257 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 43
Study 17084257 — intervention group
Group type: COMPARATOR
Intervention: Diet management
Number of subjects: 43
Study 15082464 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Psychosocial Intervention (EPI)
Number of subjects: 70
Study 15082464 — intervention group
Group type: COMPARATOR
Intervention: Minimal Psychosocial Intervention (MPI)
Number of subjects: 70
Study 11723153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of hydroxycobalamin for 5 months
Number of subjects: 16
Study 11723153 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 16
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 0800 h
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 1200 h
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 1600 h
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 2000 h
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐ and postexercise rectal temperature
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise blood pressure
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of testosterone and cortisol pre‐ and postexercise
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise‐induced responses of testosterone and cortisol
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of testosterone
Number of subjects: 10
Study 9741608 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone to cortisol ratios
Number of subjects: 10
Study 7528534 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2a, 3 million IU subcutaneously three times a week
Number of subjects: 43
Study 7528534 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 43
Study 3132853 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (Vivonex HN) delivered through a needle catheter jejunostomy
Number of subjects: 60
Study 3132853 — intervention group
Group type: COMPARATOR
Intervention: Standard 5% dextrose and electrolyte solutions
Number of subjects: 60
Study 29997147 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdilatation (postD)
Number of subjects: 124
Study 29997147 — intervention group
Group type: COMPARATOR
Intervention: No postdilatation (control)
Number of subjects: 124
Study 28625456 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron HCl (8mg, 2ml IV)
Number of subjects: 120
Study 28625456 — intervention group
Group type: COMPARATOR
Intervention: saline (2ml IV)
Number of subjects: 120
Study 25083773 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft coagulation (Group S)
Number of subjects: 111
Study 25083773 — intervention group
Group type: COMPARATOR
Intervention: Heater probe thermocoagulation (Group H)
Number of subjects: 111
Study 22990216 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 0
Study 22990216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced exposure from heavy to light
Number of subjects: 0
Study 22990216 — intervention group
Group type: COMPARATOR
Intervention: Continuing smokers
Number of subjects: 0
Study 21679528 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (Tsang‐Erh‐San extract granules and Houttuynia extract powder) for 8 weeks
Number of subjects: 97
Study 21679528 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 4 weeks
Number of subjects: 97
Study 21679528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 20175801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg co-administered with halofantrine 500 mg
Number of subjects: 15
Study 20175801 — intervention group
Group type: COMPARATOR
Intervention: Halofantrine 500 mg alone
Number of subjects: 15
Study 17107392 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated severity score
Number of subjects: 158
Study 17107392 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-rated severity score
Number of subjects: 158
Study 17107392 — intervention group
Group type: EXPERIMENTAL
Intervention: Burden of disease questionnaire (DLQI)
Number of subjects: 158
Study 17107392 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 158
Study 17107392 — intervention group
Group type: EXPERIMENTAL
Intervention: Change over time in DLQI items
Number of subjects: 158
Study 15589390 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 17
Study 15589390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11194517 — intervention group
Group type: COMPARATOR
Intervention: Infusion warmer and standard O.R. draping with two layers of cotton drapes (Group 1)
Number of subjects: 36
Study 11194517 — intervention group
Group type: COMPARATOR
Intervention: Infusion warmer and reflecting disposable insulation (Thermadrape) (Group 2)
Number of subjects: 36
Study 11194517 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion warmer and convective air warming with upper body blanket (Group 3)
Number of subjects: 36
Study 11194517 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion warmer, convective air warming and reflecting disposable insulation (Group 4)
Number of subjects: 36
Study 10345408 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded community-based services and case management
Number of subjects: 5254
Study 10345408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no expanded services)
Number of subjects: 5254
Study 1889718 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 10
Study 1889718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7120220 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antepartum biophysical screening
Number of subjects: 692
Study 31155698 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 18
Study 31155698 — intervention group
Group type: COMPARATOR
Intervention: Control (no MOPs)
Number of subjects: 18
Study 28846877 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CII) of enoxaparin 40mg over 24h for three consecutive days
Number of subjects: 39
Study 28846877 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous bolus (SCB) administration of enoxaparin 40mg once daily
Number of subjects: 39
Study 27308826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyloxapol 1% (5 ml inhaled three times daily for 3 weeks)
Number of subjects: 19
Study 27308826 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (5 ml inhaled three times daily for 3 weeks)
Number of subjects: 19
Study 27308826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyloxapol
Number of subjects: 19
Study 27308826 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 19
Study 27308826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyloxapol and Saline
Number of subjects: 19
Study 23549519 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal diabetes care
Number of subjects: 1381
Study 23549519 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1381
Study 22124067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast metal crown resembling original tooth
Number of subjects: 40
Study 22124067 — intervention group
Group type: COMPARATOR
Intervention: Cast metal crown confirmed to ideal contours
Number of subjects: 40
Study 19349629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy supplemented with up to 6 counseling calls (high‐intensity disease management)
Number of subjects: 750
Study 19349629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy supplemented with up to 2 counseling calls (moderate‐intensity disease management)
Number of subjects: 750
Study 19349629 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 750
Study 19349629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined disease management (both moderate and high intensity)
Number of subjects: 750
Study 19349629 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity disease management vs. moderate‐intensity disease management
Number of subjects: 750
Study 16399190 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 300
Study 16399190 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 300
Study 15290737 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg/week
Number of subjects: 35
Study 15290737 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 35
Study 15290737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11386927 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril, 2.5 to 10 mg/d
Number of subjects: 1094
Study 11386927 — intervention group
Group type: COMPARATOR
Intervention: amlodipine, 5 to 10 mg/d
Number of subjects: 1094
Study 9731994 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg BID for 4 weeks plus CLR 500 mg TID for the first 2 weeks
Number of subjects: 203
Study 9731994 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg BID for 4 weeks
Number of subjects: 203
Study 9731994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 9731994 — intervention group
Group type: COMPARATOR
Intervention: CLR 500 mg TID for the first 2 weeks
Number of subjects: 203
Study 9731994 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients eradicated of H. pylori infection
Number of subjects: 203
Study 9731994 — intervention group
Group type: COMPARATOR
Intervention: Patients who remained infected with H. pylori
Number of subjects: 203
Study 7837160 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT etidronate
Number of subjects: 68
Study 7837160 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no etidronate treatment)
Number of subjects: 68
Study 3422694 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow intravenous infusion of epirubicin
Number of subjects: 0
Study 3422694 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of epirubicin
Number of subjects: 0
Study 29281033 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 90
Study 29281033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/day
Number of subjects: 90
Study 29281033 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day and Aripiprazole 15 mg/day (combined)
Number of subjects: 90
Study 29281033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 26675056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency ablation (Novasure®)
Number of subjects: 104
Study 26675056 — intervention group
Group type: COMPARATOR
Intervention: Balloon endometrial ablation (Thermablate®)
Number of subjects: 104
Study 25352640 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg three times daily for 2 weeks
Number of subjects: 21
Study 25352640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23690551 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole
Number of subjects: 194
Study 23690551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 19876587 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat mesilate 200 mg three times daily for 2 weeks
Number of subjects: 95
Study 19876587 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 or no findings)
Number of subjects: 95
Study 18373286 — intervention group
Group type: EXPERIMENTAL
Intervention: C5: 2 x 5-g doses of creatine
Number of subjects: 59
Study 18373286 — intervention group
Group type: EXPERIMENTAL
Intervention: C10: 1 x 10-g dose of creatine
Number of subjects: 59
Study 18373286 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 59
Study 17240614 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.63 mg
Number of subjects: 209
Study 17240614 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 209
Study 17240614 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol 2.5 mg
Number of subjects: 209
Study 17240614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 15490770 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 603
Study 11011341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) adenosine boluses at a dose of 15 to 20 microgram in the right and 18 to 24 microgram in the left coronary artery.
Number of subjects: 52
Study 11011341 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) adenosine administered as a continuous infusion at a rate of 140 microgram/kg per minute until steady state hyperemia was achieved.
Number of subjects: 52
Study 8834004 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 5887
Study 8834004 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5887
Study 8834004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention and Control
Number of subjects: 5887
Study 8222668 — intervention group
Group type: EXPERIMENTAL
Intervention: Enucleation (removal of the eye)
Number of subjects: 0
Study 8222668 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation delivered to the tumor by means of a radioactive 'plaque'
Number of subjects: 0
Study 8222668 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 day course of external beam radiation therapy followed by enucleation
Number of subjects: 0
Study 8222668 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0
Study 3020983 — intervention group
Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge
Number of subjects: 0
Study 3020983 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm
Number of subjects: 0
Study 3020983 — intervention group
Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge (nulliparous women)
Number of subjects: 0
Study 3020983 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm (nulliparous women)
Number of subjects: 0
Study 3020983 — intervention group
Group type: EXPERIMENTAL
Intervention: Today contraceptive sponge (parous women)
Number of subjects: 0
Study 3020983 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm (parous women)
Number of subjects: 0
Study 29928603 — intervention group
Group type: EXPERIMENTAL
Intervention: L4‐5 and L5‐S1 transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 217
Study 29928603 — intervention group
Group type: COMPARATOR
Intervention: L4‐5 TLIF
Number of subjects: 217
Study 27247914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg oral 90 minutes before surgery
Number of subjects: 86
Study 27247914 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.5 mg/kg intravenous 90 seconds before intubation
Number of subjects: 86
Study 24982492 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth care delivery by front-line health professionals
Number of subjects: 32
Study 23715582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus 40 mg once per day for 5 days every week
Number of subjects: 711
Study 23715582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 23715582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus
Number of subjects: 711
Study 20884464 — intervention group
Group type: EXPERIMENTAL
Intervention: Three prunes (11.43g) soaked in water, consumed daily for 8 weeks
Number of subjects: 166
Study 20884464 — intervention group
Group type: EXPERIMENTAL
Intervention: Six prunes (23g) soaked in water, consumed daily for 8 weeks
Number of subjects: 166
Study 20884464 — intervention group
Group type: COMPARATOR
Intervention: Control group given a glass of water daily for 8 weeks
Number of subjects: 166
Study 18447225 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation combined with target-controlled infusion (TCI)
Number of subjects: 60
Study 18447225 — intervention group
Group type: COMPARATOR
Intervention: Target-controlled infusion (TCI)
Number of subjects: 60
Study 16390570 — intervention group
Group type: COMPARATOR
Intervention: Proseal laryngeal mask airway (PLMA)
Number of subjects: 82
Study 16390570 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Airway Management Device (AMD)
Number of subjects: 82
Study 14661563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous flurbiprofen 50 mg
Number of subjects: 40
Study 14661563 — intervention group
Group type: COMPARATOR
Intervention: Suppository indomethacin 50 mg
Number of subjects: 40
Study 14661563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 11340886 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% sodium bicarbonate buffered lidocaine (pH 7.2)
Number of subjects: 232
Study 11340886 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:200,000 epinephrine and 1 ml of 7.5% sodium bicarbonate
Number of subjects: 232
Study 11340886 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:200,000 epinephrine and 450 units of hyaluronidase (15 U/ml)
Number of subjects: 232
Study 11340886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 232
Study 8772331 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of oral salbutamol
Number of subjects: 0
Study 8772331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1602191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group (MDT + 8 intradermal injections of M. w. every 3 months)
Number of subjects: 87
Study 1602191 — intervention group
Group type: COMPARATOR
Intervention: Control group (MDT + starch injections as placebo)
Number of subjects: 87
Study 1602191 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 87
Study 6218755 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 48
Study 6218755 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 48
Study 30809967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar (CHI) 48 mg
Number of subjects: 0
Study 30809967 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride (MET) 1000 mg
Number of subjects: 0
Study 30809967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CHI and MET
Number of subjects: 0
Study 30303516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept and high-dose interleukin 2 (arm A)
Number of subjects: 89
Study 30303516 — intervention group
Group type: COMPARATOR
Intervention: High-dose interleukin 2 alone (arm B)
Number of subjects: 89
Study 30303516 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for arm A
Number of subjects: 89
Study 30303516 — intervention group
Group type: COMPARATOR
Intervention: Overall survival for arm B
Number of subjects: 89
Study 27650287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet (n=18) for 8 weeks
Number of subjects: 38
Study 27650287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet (n=16)
Number of subjects: 38
Study 27650287 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate/high-fibre/low-glycaemic index diet (CHO/fibre diet, n=17)
Number of subjects: 38
Study 27650287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet (n=18)
Number of subjects: 38
Study 24384945 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-cruciate-ligament-stabilized (PS) technique
Number of subjects: 100
Study 24384945 — intervention group
Group type: COMPARATOR
Intervention: Posterior-cruciate-ligament-retaining (PCR) technique
Number of subjects: 100
Study 22705426 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily distribution of RUF-Nias biscuits
Number of subjects: 99
Study 22705426 — intervention group
Group type: COMPARATOR
Intervention: Weekly distribution of RUF-Nias biscuits
Number of subjects: 99
Study 20153570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels in malnourished tuberculosis group
Number of subjects: 23
Study 20153570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels in well-nourished tuberculosis group
Number of subjects: 23
Study 20153570 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition score correlation with ghrelin
Number of subjects: 23
Study 20153570 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha and IL-6 levels in malnourished tuberculosis group
Number of subjects: 23